Israeli fund invests in HIV resistance diagnostic
This article was originally published in Clinica
Executive Summary
InnoMed, the life sciences fund of Jerusalem Global Ventures (JGV), has invested $1 million in BioVirase, which has developed a test kit to measure the resistance of the HIV virus to various drug combination regimes.